<a href="https://www.fiercebiotech.com/biotech/racing-toward-first-fda-nod-autoimmune-car-t-kyverna-bolsters-lead-full-sps-dataset" hreflang="en">Racing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS dataset</a>
Kyverna Therapeutics has presented promising results from its miv-cel trial for stiff person syndrome, which could lead to the first FDA-approved CAR-T therapy for an autoimmune disease, demonstrating significant improvements in patient mobility and symptoms. The company is also advancing miv-cel for other autoimmune conditions, including myasthenia gravis, while preparing for FDA submission amidst evolving regulatory standards.
Kyverna Therapeutics' miv-cel CAR-T therapy has shown unprecedented improvement in stiff person syndrome (SPS), a rare autoimmune disease, and could become the first CAR-T therapy approved for such conditions. The comprehensive positive results from their phase 2 KYSA-8 trial and ongoing productive discussions with the FDA suggest a strong potential for regulatory approval, marking a significant advancement in autoimmune disease treatment and offering a promising investment signal in the healthtech and biotech sectors.